Abstract: Therapeutic combinations useful in the treatment or prevention of psychotic disorders, to pharmaceutical compositions containing said combinations, and to their use in the treatment or prophylaxis of psychotic disorders are provided.
Abstract: This invention provides a method of treating pain in a mammal that includes administering to a mammal in need of such treatment a pain treating effective amount of a compound of the formula I: or a pharmaceutically acceptable salt thereof, wherein each of R1, R2, R3, n, y, and Ar is as defined and described herein. The present invention also provides pharmaceutical compositions for treating pain containing a pain treating effective amount of the compound of formula I.
Type:
Application
Filed:
April 21, 2006
Publication date:
November 16, 2006
Applicant:
Wyeth
Inventors:
Sharon Rosenzweig-Lipson, Michael Brandt
Abstract: The present invention provides methods and compositions for use in the treatment, prevention, and/or alleviation of drug abuse and/or its symptoms. In particular, the invention demonstrates that compositions comprising compounds of formula I are useful in such treatment, prevention, and/or alleviation: or a pharmaceutically acceptable salt thereof, wherein each of R1, R2, R3, Ar, y, and n are as defined herein.
Abstract: This invention provides methods and pharmaceutical compositions for modulating bladder function, and in particular for maintaining bladder control or treating urinary incontinence.
Abstract: The present invention provides a composition comprising a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein each of R1, R2, R3, y, n, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. Such compounds, and compositions thereof, are useful for treating a variety of central nervous system disorders such as schizophrenia.
Abstract: Therapeutic combinations useful in the treatment or prevention of depression or other mood disorders, to pharmaceutical compositions containing said combinations, and to their use in the treatment or prophylaxis of depression or other mood disorders are provided. Such compounds are of formula I: or a pharmaceutically acceptable salt thereof, wherein each of R1, R2, R3, n, y, and Ar are as defined and described herein.
Abstract: Compounds of the Formula: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
Abstract: Antiatherosclerotic compounds of Formula I are provided: wherein: R is lower alkyl, alkenyl, alkynyl, or —O—(CH2)n—COOR?; R? is lower alkyl; n is an integer of 1–3; Ar is phenyl, or phenyl substituted with one or more of halogen, lower alkyl, alkenyl, alkynyl, alkoxy, perfluoroalkyl, perfluoroalkoxy, or alkylthio; and pharmaceutically acceptable salts thereof.
Type:
Grant
Filed:
October 29, 2002
Date of Patent:
November 14, 2006
Assignee:
Wyeth
Inventors:
Hassan M. Elokdah, Theodore S. Sulkowski
Abstract: This invention is directed to the crystal structure of Acyl Carrier Protein Synthase (ACPS) complexed with Acyl Carrier Protein (ACP), the solution structure of B. subtilis ACP, and to the use of these structures in rational drug design methods to identify agents that may interact with active sites of ACPS and ACP, and to the testing of these agents to identify agents that may represent novel antibiotics.
Type:
Grant
Filed:
November 19, 2003
Date of Patent:
November 14, 2006
Assignee:
Wyeth
Inventors:
Kevin Delos Parris, William Stuart Somers, Amy Szepui Tam, Laura Long Lin, Mark Lloyd Stahl
Abstract: The present invention is directed to crystalline forms of the 5-HT2C agonist {[(2R)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride, as well as compositions, processes of preparation, and uses thereof.
Type:
Application
Filed:
April 21, 2006
Publication date:
November 9, 2006
Applicant:
Wyeth
Inventors:
Abdolsamad Tadayon, Qing Yu, Michel Bernatchez
Abstract: The present invention involves an assay system and method of selecting compounds useful in the treatment of bladder instability and related bladder conditions through the activation of KCNQ potassium channels in the bladder smooth muscle.
Abstract: The present invention relates to an assay system and method for testing compounds for their ability to regulate the hepatic lipase (HL) promoter. In particular, the invention relates to the identification of estrogen receptor ligands having this activity.
Type:
Application
Filed:
June 21, 2006
Publication date:
November 9, 2006
Applicant:
Wyeth
Inventors:
Douglas Harnish, Marshall Scicchitano, Sotirios Karathanasis, Chu-Lai Hsiao
Abstract: The present disclosure is directed to combination therapies of tigecycline and heparin and methods of administration of tigecycline and heparin.
Type:
Application
Filed:
May 5, 2006
Publication date:
November 9, 2006
Applicant:
Wyeth
Inventors:
Stephen Ludwig, Maja Vencl-Joncic, Pooja Gandhi, Joseph Gross, Julianna Koczone
Abstract: The present invention relates to new 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compounds having the general structures below: which are useful in treating uterine leiomyoma.
Type:
Grant
Filed:
December 13, 2005
Date of Patent:
November 7, 2006
Assignee:
Wyeth
Inventors:
Chris P. Miller, Michael D. Collini, Bach D. Tran, Arthur A. Santilli
Abstract: Methods and kits for preventing or minimizing the formation of isatin oximes during formation of an isatin from an isonitrosoacetanilide are provided. Also provided are methods and kits for preventing or minimizing the formation of isatin oxime impurities after formation of an isatin from an isonitrosoacetanilide by using a decoy agent in the quenching and/or extraction steps. The isatins can be prepared using a decoy agent and desirably a strong acid. Further provided are methods for preparing isatin oximes.
Type:
Application
Filed:
April 27, 2006
Publication date:
November 2, 2006
Applicant:
Wyeth
Inventors:
Bogdan Wilk, Panolil Raveendranath, Zhixian Ding, Peter Wehrenberg
Abstract: Novel proteins which bind human ?-amyloid peptide, polynucleotides which encode these proteins, and methods for producing these proteins are provided. Diagnostic, therapeutic, and screening methods employing the polynucleotides and polypeptides of the present invention are also provided. Transgenic animals and knockout animals are also provided.
Type:
Application
Filed:
July 12, 2006
Publication date:
November 2, 2006
Applicant:
Wyeth
Inventors:
Bradley Ozenberger, Jonathan Bard, Eileen Kajkowski, Jack Jacobsen, Stephen Walker, Heidi Sofia, David Howland
Abstract: Compounds of formula I are provided: wherein each of R1, R2, y, m, n, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of melatoninergic receptors. The compounds, and compositions containing the compounds, can be used to treat melatoninergic disorders.
Abstract: Methods for preparing oxindole and thio-oxindole compounds are provided, which compounds are useful as precursors to useful pharmaceutical compounds. Specifically provided are methods for preparing 5-pyrrole-3,3-oxindole compounds and 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile. Also provided are methods for preparing iminobenzo[b]thiophene and benzo[b]thiophenone compounds.
Abstract: Compositions, preferably pharmaceutical compositions, containing micronized tanaproget, or pharmaceutically acceptable salt thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, butylated hydroxyanisole, povidone, and magnesium stearate, are provided. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake.